Moderna mRNA vaccine almost halves the risk of skin cancer returning

T1Covered by 1 source · first reported by Nature / Science / Nature Biotechnology at 23 Oct, 00:00 UTC

Nature, Published online: 23 October 2026; doi:10.1038/d41586-026-03417-0 Long-awaited results from phase III trial show huge benefits for treatment-resistant melanoma.